(Q37960512)

26 August 2017

title

Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia (English)

1 reference

26 August 2017

0 references

Maria J. Arranz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22114782

18 December 2024

Janet C. Munro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22114782

18 December 2024

language of work or name

English

0 references

publication date

1 May 2011

1 reference

26 August 2017

May 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22114782

full work available at URL

18 December 2024

http://www.future-drugs.com/doi/abs/10.1586/ecp.11.16

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22114782

http://www.tandfonline.com/doi/pdf/10.1586/ecp.11.16

18 December 2024

1 reference

Expert Review of Clinical Pharmacology

18 December 2024

published in

1 reference

26 August 2017

volume

4

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

389-405

1 reference

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

26 August 2017

cites work

1 reference

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review

21 January 2018

1 reference

Relapse in schizophrenia: costs, clinical outcomes and quality of life

21 January 2018

1 reference

Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

21 January 2018

1 reference

Olanzapine: concordant response in monozygotic twins with schizophrenia

21 January 2018

1 reference

Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs

21 January 2018

1 reference

Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation

21 January 2018

1 reference

21 January 2018

1 reference

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

21 January 2018

1 reference

Review: The biological basis of antipsychotic response in schizophrenia

21 January 2018

1 reference

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability

21 January 2018

1 reference

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

21 January 2018

1 reference

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

21 January 2018

1 reference

Half a century of antipsychotics and still a central role for dopamine D2 receptors

21 January 2018

1 reference

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis

21 January 2018

1 reference

DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients

21 January 2018

1 reference

Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients

21 January 2018

1 reference

Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole

21 January 2018

1 reference

Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population

21 January 2018

1 reference

The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms

21 January 2018

1 reference

Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function

21 January 2018

1 reference

Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia

21 January 2018

1 reference

Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia

21 January 2018

1 reference

Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

21 January 2018

1 reference

Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients

21 January 2018

1 reference

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene

21 January 2018

1 reference

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

21 January 2018

1 reference

Clinical applications of pharmacogenetics in psychiatry

21 January 2018

1 reference

Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia

21 January 2018

1 reference

Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

Dopamine D3 receptor Ser9Gly polymorphism and risperidone response

21 January 2018

1 reference

Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant

21 January 2018

1 reference

Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine

21 January 2018

1 reference

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

21 January 2018

1 reference

Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs.

21 January 2018

1 reference

Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia.

21 January 2018

1 reference

Antipsychotics and dopamine transporter gene polymorphisms in delirium patients

21 January 2018

1 reference

Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.

21 January 2018

1 reference

COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia

21 January 2018

1 reference

Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics

21 January 2018

1 reference

Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.

21 January 2018

1 reference

Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications

21 January 2018

1 reference

Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.

21 January 2018

1 reference

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene

21 January 2018

1 reference

Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine.

21 January 2018

1 reference

Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics

21 January 2018

1 reference

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting

21 January 2018

1 reference

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

21 January 2018

1 reference

The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity

21 January 2018

1 reference

HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients

21 January 2018

1 reference

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor

21 January 2018

1 reference

Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders

21 January 2018

1 reference

Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients

21 January 2018

1 reference

The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.

21 January 2018

1 reference

Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response.

21 January 2018

1 reference

Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis

21 January 2018

1 reference

Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics

21 January 2018

1 reference

Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients

21 January 2018

1 reference

Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients

21 January 2018

1 reference

Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.

21 January 2018

1 reference

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia.

21 January 2018

1 reference

Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine

21 January 2018

1 reference

Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene

21 January 2018

1 reference

Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study

21 January 2018

1 reference

Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients

21 January 2018

1 reference

A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels

21 January 2018

1 reference

Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study

21 January 2018

1 reference

MDR1 gene polymorphisms and response to acute risperidone treatment

21 January 2018

1 reference

Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication

21 January 2018

1 reference

G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics

21 January 2018

1 reference

RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia

21 January 2018

1 reference

Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics

21 January 2018

1 reference

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

21 January 2018

1 reference

Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response

21 January 2018

1 reference

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

21 January 2018

1 reference

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine

21 January 2018

1 reference

The impact of pharmacogenetics on the development and use of antipsychotic drugs

21 January 2018

1 reference

A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone

21 January 2018

1 reference

Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions

21 January 2018

1 reference

Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene

21 January 2018

1 reference

Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome

21 January 2018

1 reference

Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors

21 January 2018

1 reference

The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX.

21 January 2018

1 reference

Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis

21 January 2018

1 reference

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

21 January 2018

1 reference

A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.

21 January 2018

1 reference

Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment

21 January 2018

1 reference

No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study

21 January 2018

1 reference

Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients

21 January 2018

1 reference

Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms

21 January 2018

1 reference

Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region

21 January 2018

1 reference

Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP).

21 January 2018

1 reference

Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia

21 January 2018

1 reference

Association study of serotonergic gene variants with antipsychotic-induced adverse reactions

21 January 2018

1 reference

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

21 January 2018

1 reference

Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine

21 January 2018

1 reference

The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients

21 January 2018

1 reference

HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study

21 January 2018

1 reference

Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.

21 January 2018

1 reference

Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.

21 January 2018

1 reference

Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain

21 January 2018

1 reference

-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals

21 January 2018

1 reference

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients

21 January 2018

1 reference

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis

21 January 2018

1 reference

ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics

21 January 2018

1 reference

Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment

21 January 2018

1 reference

Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain

21 January 2018

1 reference

Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans.

21 January 2018

1 reference

Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype

21 January 2018

1 reference

Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility.

21 January 2018

1 reference

Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia

21 January 2018

1 reference

A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia

21 January 2018

1 reference

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia

21 January 2018

1 reference

Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients

21 January 2018

1 reference

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

21 January 2018

1 reference

Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

CYP2D6 polymorphisms and atypical antipsychotic weight gain.

21 January 2018

1 reference

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

21 January 2018

1 reference

MTHFR and risk of metabolic syndrome in patients with schizophrenia

21 January 2018

1 reference

Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants

21 January 2018

1 reference

Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes

21 January 2018

1 reference

Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients

21 January 2018

1 reference

Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

21 January 2018

1 reference

Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.

21 January 2018

1 reference

Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia

21 January 2018

1 reference

Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication.

21 January 2018

1 reference

SNAP-25 gene polymorphisms and weight gain in schizophrenic patients

21 January 2018

1 reference

Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients.

21 January 2018

1 reference

Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.

21 January 2018

1 reference

C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population

21 January 2018

1 reference

BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia

21 January 2018

1 reference

BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population

21 January 2018

1 reference

Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia

21 January 2018

1 reference

Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan

21 January 2018

1 reference

Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia

21 January 2018

1 reference

Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes

21 January 2018

1 reference

Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness

21 January 2018

1 reference

Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample.

21 January 2018

1 reference

HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients

21 January 2018

1 reference

An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201.

21 January 2018

1 reference

Influence of pharmacogenetics on drug disposition and response

21 January 2018

1 reference

Treatment adherence in chronic disease

21 January 2018

1 reference

Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis

21 January 2018

1 reference

Schizophrenia genetics: advancing on two fronts

21 January 2018

1 reference

Copy number variation and schizophrenia

21 January 2018

1 reference

Accounting for multiple comparisons in a genome-wide association study (GWAS)

21 January 2018

1 reference

A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses

21 January 2018

1 reference

Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia

21 January 2018

1 reference

Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.

21 January 2018

1 reference

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.

21 January 2018

1 reference

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients

21 January 2018

1 reference

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

21 January 2018

1 reference

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

21 January 2018

1 reference

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia

21 January 2018

1 reference

Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches

21 January 2018

1 reference

Pharmacogenetic testing in psychiatry: a review of features and clinical realities.

21 January 2018

1 reference

Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients

21 January 2018

1 reference

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

21 January 2018

1 reference

Genetic variation of the 5-HT2A receptor and response to clozapine

21 January 2018

1 reference

Pharmacogenetic prediction of clozapine response

21 January 2018

1 reference

Familial occurrence of tardive dyskinesia

21 January 2018

1 reference

Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population

21 January 2018

1 reference

Dopamine D3 receptor variant and tardive dyskinesia

21 January 2018

1 reference

CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY

21 January 2018

1 reference

The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia

21 January 2018

1 reference

Evaluation of Treatment-Resistant Schizophrenia

21 January 2018

2

1 reference

The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree

18 December 2024

7

1 reference

Monozygotic twins concordant for response to clozapine

18 December 2024

8

1 reference

Clozapine-induced concordant agranulocytosis in monozygotic twins

18 December 2024

9

1 reference

The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients

18 December 2024

32

1 reference

Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia

18 December 2024

46

1 reference

Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects

18 December 2024

48

1 reference

DRD3 and DAT1 genes in schizophrenia: an association study

18 December 2024

52

1 reference

Association between clozapine response and allelic variation in 5-HT2A receptor gene

18 December 2024

64

1 reference

Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine

18 December 2024

66

1 reference

Serotonin-6 receptor variant (C267T) and clinical response to clozapine

18 December 2024

75

1 reference

Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia

18 December 2024

96

1 reference

Neuregulin genotype and medication response in Finnish patients with schizophrenia

18 December 2024

103

1 reference

Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients

18 December 2024

111

1 reference

Pharmacogenetics of antipsychotic-induced weight gain

18 December 2024

127

1 reference

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.

18 December 2024

129

1 reference

An investigation of theα1A-adrenergic receptor gene and antipsychotic-induced side-effects

18 December 2024

145

1 reference

Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome

18 December 2024

154

1 reference

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism

18 December 2024

156

1 reference

Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients

18 December 2024

158

1 reference

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study

18 December 2024

159

1 reference

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

18 December 2024

163

1 reference

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms

18 December 2024

167

1 reference

CYP2D6 Polymorphism and Tardive Dyskinesia in Schizophrenic Patients

18 December 2024

168

1 reference

Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability

18 December 2024

180

1 reference

Association between clozapine-induced agranulocytosis and HLA subtyping.

18 December 2024

192

1 reference

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

18 December 2024

194

1 reference

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature

18 December 2024

197

1 reference

18 December 2024

Identifiers

DOI

10.1586/ECP.11.16

1 reference

26 August 2017

1 reference